SCHEMBL4957199

SCHEMBL4957199

NS(=O)(=O)c1ccc(C(=O)Nc2nc3c(s2)Cc2cc(F)ccc2-3)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 16/20 0.61
TP53 P04637 7/20 0.61
ALDH1A1 P00352 7/20 0.61
SMN1; SMN2 Q16637 7/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
APAF1 O14727 3/20 0.61
BLM P54132 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2C9 P11712 2/20 0.61
CYP2C19 P33261 2/20 0.61
TDP2 O95551 2/20 0.61
CASP3 P42574 1/20 0.61
MCL1 Q07820 1/20 0.61
SENP8 Q96LD8 1/20 0.61
SENP7 Q9BQF6 1/20 0.61
SENP6 Q9GZR1 1/20 0.61
KDM4E B2RXH2 4/20 0.56
NPC1 O15118 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4961540 0.85 KDM4E (0.59) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL4963945 0.81 MAPT (0.60) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL4958725 0.79 ADORA1 (0.60) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL4958411 0.77 MAPT (0.57) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL4958817 0.76 MAPT (0.52) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL7840997 0.75 SMN1; SMN2 (0.56) MAPTSMN1; SMN2MEN1KMT2ACYP2C9
SCHEMBL7842901 0.75 SMN1; SMN2 (0.56) MAPTSMN1; SMN2MEN1KMT2ACYP2C9
SCHEMBL4960364 0.74 MAPT (0.73) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL4958350 0.72 MAPT (0.68) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL1822988 0.71 MAPT (0.70) MAPTTP53ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407977-B2 Substituted N-acyl-2-aminothiazoles HOFFMAN-LA ROCHE INC. (US) 2008-08-05 US disclosed
EP-1791822-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-06 EP disclosed
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles HOFFMANN-LA ROCHE INC. 2006-02-09 US disclosed
WO-2006013054-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles SLC5A2, ABAT, AGTR2 MAPT 1360/4885TP53 4777/4885ALDH1A1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.